# Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

> **NCT02452047** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 50 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Imipenem+Cilastatin/Relebactam
- **DRUG:** Colistimethate sodium (CMS)
- **DRUG:** Imipenem+Cilastatin
- **DRUG:** Placebo to CMS

## Key facts

- **NCT ID:** NCT02452047
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-21
- **Primary completion:** 2017-09-18
- **Final completion:** 2017-09-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452047, "Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02452047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*